All Activity

Thanks for sharing this valuable post. The information is clear, useful, and easy to follow. I really appreciate the effort, Best iptv

“This bill is more than a policy change—it offers real hope to so many people who desperately need it.” By Jack Gorsline, Filter The Oklahoma State Senate voted on April 29 to pass the Oklahoma Breakthrough Therapy Act. Formally known as House Bill 3834, the measure authorizes the use of state funds to support trials focused on ibogaine—the powerful, naturally occurring psychedelic compound. The bill passed the House in March. If signed into law by Governor Kevin Stitt (R), it will mark a significant shift in Oklahoma’s approach to the ongoing crises around mental health and substance use disorders. It would authorize the State Department of Health to enter into contracts with drug developers to conduct extensive, state-monitored clinical trials for ibogaine-based therapeutics. Lawmakers who championed the bill argue that traditional treatment methods have consistently fallen short, necessitating a research-driven exploration of breakthrough therapies. The legislation is also designed to facilitate collaboration with other states currently conducting similar clinical research, creating a multistate consortium aimed at securing federal regulatory approval. Ibogaine is derived from the root bark of the iboga shrub. For decades, the compound has shown observational promise in interrupting severe substance use disorders—particularly opioids—and alleviating post-traumatic stress disorder and traumatic brain injuries. However, because ibogaine is federally classified as a Schedule I controlled substance, it remains illegal to possess, distribute or administer outside of highly restricted research settings. This has seen desperate patients seek unregulated and costly treatments abroad. Ibogaine use for these purposes is not without controversy or risk. There are well-documented medical hazards, most notably the potential for severe cardiac complications, which have led to efforts to develop safer versions of the compound. There are also risks around resumed opioid use with lowered tolerance if ibogaine is used for withdrawal and abstinence. Recognizing these issues, proponents of the Oklahoma bill stress that state-sponsored clinical trials would bring the treatment out of the unregulated shadows and into highly controlled medical environments. Under the proposed framework, patients would undergo rigorous pre-treatment medical evaluations and receive the drug under continuous monitoring by medical professionals. To mitigate financial risk to the state and seek a high standard of research, the bill imposes requirements on participating drug developers. Any drug developer contracting with the health department would have to match the state’s financial investment in the trials dollar-for-dollar Developers would additionally be required to submit a detailed plan for obtaining approval from the U.S. Food and Drug Administration (FDA), along with protocols for trial participant recruitment, patient screening criteria, safety and post-acute treatment support. The bill also mandates that drug developers prioritize treatment access for Oklahoma residents once FDA approval is secured. And the legislation requires a plan to protect the state’s economic interest in any intellectual property generated. The idea is that if the trials yield a profitable, FDA-approved therapeutic, funds will come back to the state. The legislation establishes a dedicated revolving fund to capture any proceeds. By law, this money could only be utilized for programs or further research that directly benefit at-risk Oklahomans with conditions treatable by ibogaine. The bill grants medical professionals professional immunity too, shielding them from adverse licensing actions by state medical boards for recommending these trials to their patients. The passage of House Bill 3834 through the Senate represents a major victory for a coalition of patient advocates, veterans and others. These groups have spent months sharing deeply personal stories of addiction, trauma and recovery with state lawmakers, aiming to demystify ibogaine and highlight its potential. “Oklahoma for Ibogaine is celebrating the passing of HB 3834 through the Senate,” Nate Morgans, an Oklahoma-based psychedelics advocate and CEO of the Casey Skudin 343 Fund, told Filter. “Our team has worked tirelessly since December to educate, inform, and persuade Oklahoma legislators on the importance of authorizing and funding FDA clinical trials of Ibogaine. This initiative was led by a grassroots effort, employed no lobbyists, and focused on education through truly lived experiences. Our success today serves as a testament to what can be accomplished with determined hearts.” In recent months, other state legislatures have begun viewing ibogaine research as a pragmatic health care response. In March, for instance, Mississippi Gov. Tate Reeves (R) signed similar legislation. The Mississippi law authorizes the state to form a consortium to conduct ibogaine clinical trials in direct coordination with other participating states—most notably neighboring Texas, which has already committed substantial funding to psychedelic research. While Mississippi’s new law establishes the legal and administrative framework for the clinical trials, the new law does not currently appropriate state general funds toward the program. However, state lawmakers have indicated their intent to allocate a portion of the state’s federal opioid settlement funds to support the initiative. Advocates are divided over such uses of money that could otherwise be funding under-resourced harm reduction efforts. State efforts to establish ibogaine clinical trials have not been uniformly successful. In April, a similar bill in West Virginia was derailed, after Gov. Patrick Morrisey (R) vetoed it. The bill would have established a state grant program to fund ibogaine drug development trials. It passed the state legislature, but Morrisey cited fiscal concerns in his veto message. Before killing the bill in the hours leading up to the state’s legislative deadline, he said that while he supports this medical innovation in principle, “we should do so without requiring the state to award grants of undefined and unfunded amounts.” Despite such setbacks and controversies, advocates for ibogaine access and development remain optimistic about growing national momentum. “This bill is more than a policy change—it offers real hope to so many people who desperately need it,” Chase Rowan told Filter of the Oklahoma bill. A US Army Ranger veteran, Rowan serves as both the veteran coordinator for Texans for Greater Mental Health and the director of Community Engagement & Advocacy for Americans for Ibogaine. It’s a development that will “offer hope” to veterans and their families, including those impacted by substance use disorders, he said, and who have “tried every conventional method known to man, with no success.” “Hello, Ibogaine, now we have an answer,” Rowan continued, “a real legitimate answer, something we can study, a medicine that will help so many people find true healing. Exciting things to come in the world of healing.” The Oklahoma Breakthrough Therapy Act now heads to Stitt’s desk, where it remains to be seen if it will be signed into law. This article was originally published by Filter, an online magazine covering drug use, drug policy and human rights through a harm reduction lens. Follow Filter on Bluesky, X or Facebook, and sign up for its newsletter. Photo courtesy of Flickr/Scamperdale. The post Oklahoma Lawmakers Pass Ibogaine Bill, Sending Psychedelic Reform To Governor’s Desk appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The California Assembly has passed a bill that would allow marijuana retailers to offer drive-thru windows to serve customers. The measure, which was approved in a floor vote of 55-9 on Monday, says that licensed cannabis retailers and microbusinesses with storefronts could sell marijuana products “to a customer in a motor vehicle in a drive-through located on the premises.” It previously cleared the Assembly Appropriations Committee and Business and Professions Committee, and next heads to the Senate for consideration. Under AB 2697 from Assemblymember Gail Pellerin (D), cannabis businesses would need approval from the local jurisdictions in which they operate in order to add the drive-thru option. The sponsor said on the floor that the bill “will expand access to legal cannabis products while strengthening legal market’s ability to compete with the illicit market.” Pellerin and supporters have testified that the legislation will help make legal cannabis more accessible, especially for medical patients who may find it difficult to get out of their cars. “California cannabis retailers lack a common and accessible transaction path for consumers afforded so many other retailers in California, including fast food, pharmacies, banks and even liquor stores,” Pellerin previously said. “Cannabis consumers who have mobility issues or other disabilities have limited options for being able to obtain cannabis without having to step out of their vehicles. And while home delivery is legal, there are service area restrictions,” she said. “Allowing cannabis retailers to add the consumer-friendly option of a secured drive through, if approved by the local jurisdiction, will enhance the consumer experience, increase safety at cannabis retailers, and help expand California’s legal cannabis marketplace.” The California Narcotic Officers’ Association opposes the proposal, however, arguing that “while intended to promote convenience, this retail model introduces elevated risks related to impaired driving, regulatory compliance, crime exposure, and traffic safety.” “Importantly, no similar statute authorizes drive-thru window liquor sales. Drive-thru window cannabis sales create a direct nexus between purchase and vehicle operations,” the police group said. “This will increase the likelihood of drug-impaired driving incidents and deaths by encouraging the immediate or near-immediate consumption following the purchase of edible and high-potency products resulting in dangerous impairment.” Under a current policy enacted during the height of the COVID pandemic, dispensaries can already offer curbside pickup. The bill that is advancing in the legislature would mandate that drive-thru sales “shall occur through a fixed-pane security window with a security drawer or similar secure transfer mechanism that is part of a building located within the premises.” — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — California regulators recently adopted changes to the state’s marijuana licensing process that are intended to make it easier for businesses to qualify for benefits in line with the Trump administration’s recent move to federally reschedule medical cannabis. Gov. Gavin Newsom (D), meanwhile, recently took credit for helping to lead the push for the state to legalize marijuana and discussed his own limited experience with using cannabis. In October, however, Newsom vetoed a bill that would have allowed certain marijuana microbusinesses to ship medical cannabis products directly to patients via common carriers like FedEx and UPS, stating that the proposal “would be burdensome and overly complex to administer.” Newsom did sign a bill earlier that month aimed at streamlining research on marijuana and psychedelics. In September, the governor also signed a measure into law to put a pause on a recently enacted tax hike on marijuana products. California officials recently awarded nearly $30 million in grants for marijuana-focused academic research projects. The post California Assembly Passes Bill To Legalize Marijuana Dispensary Drive-Thru Windows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

If board members object to a federal change, they must publicly issue their reasons and allow for a hearing process before any state action moves forward. By Casey Smith, Indiana Capital Chronicle Indiana lawmakers could soon revisit debates over medical marijuana legalization, but state officials say it remains unclear when—or if—federal marijuana reclassification will formally trigger action in Indiana. At a Monday meeting, the Indiana Board of Pharmacy reviewed a federal notice related to marijuana rescheduling but took no formal action. Board members said any future state response depends on the federal process becoming official. That means Indiana’s marijuana laws remain unchanged, for now. Even so, Republican Sen. Mike Bohacek announced on Monday his plans to draft 2027 legislation that would legalize medical marijuana in Indiana and establish regulations governing its sale, distribution and use. Bills for the 2027 session can’t be filed until later this year. “In light of the governor’s openness to consider legislation regarding the legalization of marijuana, we need to consider a feasible marijuana policy that would be the most helpful to Hoosiers and the economy,” Bohacek, of Michiana Shores, said in a statement. “The use of medical marijuana has been proven to be beneficial for some medical disorders and could help people throughout the state who are suffering find some relief.” The senator said his proposal would legalize medical marijuana, establish rules for medical use, create a tax structure for marijuana sales and distribution and update Indiana’s impairment laws related to THC use. The announcement sets up another likely marijuana debate at the Statehouse after years of failed efforts to loosen Indiana’s cannabis laws. Gov. Mike Braun (R) last month also signaled openness to broader discussions about marijuana legalization and regulation in Indiana. The governor stopped short of endorsing full legalization but said he was open to reviewing policy recommendations and hearing proposals from lawmakers on how Indiana should approach marijuana regulation moving forward. Although the U.S. Department of Justice last month announced limited Schedule III reclassification for certain state-licensed medical marijuana products, broader federal marijuana rescheduling remains tied up in an ongoing Drug Enforcement Administration process that has not yet been finalized. Federal hearings on broader rescheduling are scheduled to begin in June. The proposed federal change would move state-approved medical marijuana from Schedule I—reserved for drugs with no accepted medical use—to Schedule III, a less restrictive category that recognizes some medical uses. Leif Johnson, a lawyer for the state pharmacy board, said Monday that Indiana law requires the board to review any finalized federal scheduling change and determine whether the state will object to adopting similar changes under Indiana law. Under Indiana Code, the pharmacy board is tasked with reviewing controlled-substance scheduling changes and recommending whether the state should adopt comparable classifications. If board members object to a federal change, they must publicly issue their reasons and allow for a hearing process before any state action moves forward. Indiana remains among a shrinking number of states without a medical marijuana program, even as neighboring states have expanded legalization efforts. Multiple proposals to legalize or decriminalize marijuana—including limited medical-use bills—have repeatedly stalled in the General Assembly in recent legislative sessions. Earlier this year, Indiana lawmakers again failed to reach agreement on cannabis-related policy changes. A Senate-approved proposal to crack down on intoxicating hemp-derived THC products died before the legislature adjourned. Bohacek emphasized that his bill would not legalize recreational marijuana, though. “While the legislation I plan to propose would legalize the use of medical marijuana, it would not take away from the safety standards that would need to be established to keep Hoosiers safe,” he said. “This proposed legislation would not legalize the use of recreational marijuana.” Bohacek additionally said he plans to build “plenty of parameters” into the legislation governing how medical marijuana would be distributed and regulated in Indiana. “I intend to include plenty of parameters around the implementation and use of medical marijuana to ensure it’s being properly regulated and distributed by Hoosier healthcare professionals,” Bohacek said. He maintained that the legislation would establish THC impairment standards and additional law enforcement training requirements. “Many of our state’s current laws regarding the use of marijuana would remain in place, with some adjustments to account for those who may have medical exemptions,” Bohacek said. The senator argued, too, that Indiana should consider regulating and taxing marijuana products already widely available in the state. “Indiana has already allowed the sale of delta-8 THC and other similar cannabinoids, so creating a tax policy is a logical next step in expanding the use of THC products,” Bohacek said. “There is potential to bring in millions of dollars in tax revenue every year.” This story was first published by Indiana Capital Chronicle. The post Indiana Board Of Pharmacy Discusses Federal Marijuana Rescheduling’s Impact On State Policy appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A powerful congressional committee is expected to approve a report this week that directs federal officials to take enforcement action against unregulated cannabinoid products that “threaten consumer safety.” The House Appropriations Committee on Wednesday is set to take up a Fiscal Year 2027 spending bill covering Commerce, Justice, Science, and Related Agencies, as well as an attached report that includes the directive. It calls on the Drug Enforcement Administration (DEA) and Food and Drug Administration (FDA) to address the “proliferation of Federally unregulated ingestible, inhalable, and topical products that contain intoxicating cannabinoids.” “Intoxicating Cannabidiols.—The Committee is concerned by the proliferation of Federally unregulated ingestible, inhalable, and topical products that contain intoxicating cannabinoids. The Committee directs the DEA, in coordination with the FDA Office of Inspections and Investigations, to take appropriate enforcement actions against those whose products threaten consumer safety and fail to meet the statutory definition of section 10113 of Public Law 115–334 and section 781 of Public Law 119–37. The Committee further directs the DEA to report on these efforts and any resources necessary to enforce the controlled substance laws and regulations of the United States not later than 90 days after the enactment of this Act.” While the provision doesn’t use the word “hemp,” it cites statutes covering the crop and appears responsive to widespread sales of products derived from it after they became legal under the 2018 Farm Bill. Congress has since passed, however, and President Donald Trump has signed, new legislation that will broadly recriminalize hemp THC products starting in November. The new appropriations report, meanwhile, also calls on the Department of Justice to take action against “money laundering schemes” tied to Chinese-connected illegal marijuana grow operations within the U.S. “Chinese Communist Party (CCP) Money Laundering.—The Committee directs the Department to utilize funds directed to anti-money laundering programs to investigate potential money laundering schemes involving CCP-connected marijuana businesses and entities providing financial services to these businesses.” Finally, the report notes that funding is being set aside for the Bureau of Prisons (BOP) to monitor wastewater to detect use of synthetic cannabinoids and other drugs by incarcerated people. “Wastewater Surveillance Pilot.—The Committee provides $8,500,000 to BOP to carry out a pilot program using a wastewater surveillance system to monitor the prevalence of infectious diseases—including Hepatitis C, HIV, tuberculosis, and respiratory pathogens—as well as the use of covered drugs, including fentanyl, nitazenes, and other synthetic opioids, methamphetamine, synthetic cannabinoids, and other controlled substances, among the incarcerated population at not fewer than six Federal correctional institutions. Sites will be selected to ensure representation across security classification levels, geographic regions of the United States, and institutional population sizes. Not later than 180 days after the completion of the pilot program, BOP shall submit a report detailing findings regarding the prevalence of infectious diseases and covered drug use at participating institutions, along with recommendations for legislative or administrative action.” The underlying spending legislation that the report is attached to, meanwhile, contains a provision to block federal officials from taking further steps to reschedule cannabis. It also includes an updated version of a longstanding rider that since 2014 has protected state medical cannabis programs from federal interference. The House Appropriations Committee last month approved a separate spending bill and an attached report that expresses concerns about health risks from cannabis-derived products, while also encouraging research into the therapeutic benefits of psychedelics. The full House also recently passed a Farm Bill with provisions aimed at aiding industrial hemp producers—but without any language to delay or alter the federal recriminalization of hemp THC products that’s scheduled to take effect later this year. The House Rules Committee is considering an amendment this week that would allow military veterans to receive recommendations for medical marijuana through their doctors at the Department of Veterans Affairs (VA). A new report from the Congressional Research Service details the scope and limitations of the federal marijuana rescheduling move. The post Congressional Committee Directs DEA To Crack Down On Unregulated Cannabis Products That ‘Threaten Consumer Safety’ appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I cannot wait to dig deep and kickoff utilizing resources that I received from you. Your exuberance is refreshing. 성인 피시방

Ohio officials are launching a public education campaign about the risks of marijuana use—an effort that involves partnering with an organization behind a new poll that shows widespread support for legalization and broad acceptance of cannabis use among the state’s residents. Ohio Gov. Mike DeWine (R) touted the campaign, which will be overseen by the Department of Commerce (DOC) and supported by $20 million appropriated by lawmakers under the state’s marijuana law, on Monday. DOC will collaborate with the OneOhio Recovery Foundation on the awareness initiative. “Since my first day in office, combating addiction and protecting the health of Ohio families has been a top priority for our administration,” DeWine said in a press release. “With non-medical marijuana now legal in Ohio, it’s more important than ever that Ohioans—especially young people and mothers—have access to accurate information and understand the real consequences of use.” While state officials pointed to recent polling from the OneOhio Recovery Foundation to justify the outreach effort—noting findings that show increase use of cannabis among adults since non-medical sales started in 2024, for example—the survey also included several takeaways underscoring public support for the reform. For example, 60 percent of Ohioans agreed that legalization “has been good for local communities,” compared to just 17 percent who disagreed. Another 53 percent “believe that their community would be better off if more adults used marijuana on a regular basis,” the polling report says. All told, about 2 in 5 Ohio adults (41 percent) said they consume cannabis in some form, including 56 percent of those under 55 years old. “Ohioans believe that using marijuana is relatively safe and is more acceptable now that it is legal,” the report from Public Opinion Strategies says, with 62 percent of Ohioans believing cannabis is a “relatively innocent drug that poses few risks to users” compared to other drugs. Among current cannabis consumers, 81 percent said the same. “Not only do 59 percent of Ohioans believe that recreational marijuana usage is safe, but 67 percent of all Ohioans agree that since marijuana is legal to use in the state, it is now more acceptable to use it,” the foundation’s survey found. “Ohioans just don’t believe that marijuana poses significant risks to its users.” “Reinforcing that finding, nearly 60 percent of Ohioans believe that recreational marijuana usage is safe. Fully 68 percent of marijuana users in the state agree that ‘using marijuana poses very little risk to my health.’ Likewise, most current marijuana users believe that marijuana usage has a positive effect on most people.” Men were more likely to report using marijuana (49 percent) than women (34 percent). Rates of usage were largely equitable across education levels, with 42 percent of high school graduates, 39 percent of those with some college experience and 43 percent of college graduates reporting cannabis consumption. Ohioans living in what the pollster described as “big” cities were about twice as likely to use marijuana (69 percent) than those living in more rural areas of the state (35 percent). Partnering with @1OhioFoundation, we’re launching a new statewide campaign to help Ohioans understand the health and safety risks of marijuana use. We’re starting with a maternal health focus and expanding through multi channel outreach. Learn more: https://t.co/k2As2KeC5C pic.twitter.com/BIfUBa1MLb — Ohio Commerce (@OhioCommerce) May 11, 2026 The survey involved interviews with 2,000 Ohio adults from February 23-March 1, with a +/-2.5 percentage point margin of error. The OneOhio Recovery Foundation, which commissioned the poll, says it was “created at the direction of Ohio’s state and local leaders to distribute 55 percent of the funds our state will receive from the pharmaceutical industry as a consequence of its role in the national opioid epidemic.” The organization’s board includes members appointed by the governor and attorney general, as well as leaders of the Senate and House of Representatives. Despite the widespread support for legalization and belief in the relatively safety of cannabis demonstrated by the survey, DeWine’s administration is promoting the partnership opportunity with the foundation as it gears-up for what it described as a “coordinated, multi-channel outreach effort to deliver clear, evidence-based information to Ohioans.” The first phase of the effort, which is set to launch this summer, will focus on promoting information about the health risks of using marijuana in the context of maternal health. That will be expanded to promote awareness around marijuana and youth—with paid media, community partnerships and “on-the-ground outreach coordinated by the Foundation.” OneOhio Recovery Foundation Executive Director Alisha Nelson said the organization is “seeing growing misconceptions about the risks associated with marijuana, and this campaign responds directly to what the research is telling us.” “Too many people underestimate those risks, especially for young people and during pregnancy,” Nelson said. “This effort is about ensuring Ohioans have clear, accurate information to protect their health and make informed decisions to safeguard their futures.” “As we recognize Maternal Health Awareness Month in May, we are preparing to launch a campaign that meets moms-to-be with information they can trust. Our goal is to help expectant mothers understand the risks of marijuana use during pregnancy, encourage open conversations with healthcare providers and connect families with resources to support healthy decisions.” — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile in Ohio, a law recently took effect undermining certain marijuana rules under the state’s voter-approved legalization statute, as well as rules for intoxicating hemp cannabinoid products. But the new law continues to be contested by cannabis businesses in court. Photo courtesy of Mike Latimer. The post Most Ohioans See Marijuana As ‘Safe’ And ‘Acceptable,’ New Poll Shows As State Officials Launch Campaign Highlighting Risks Of Use appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Engage with our escorts in Chawri Bazar. You can enjoy the most rewarding sexual experiences with our alluring girls. Our Escort Service in Chawri Bazar do not include veiling. You can find high-quality women for companionship. We are open to discussing your sexual desires. Reach out to us today for the most unique enjoyable experience at a budget-friendly rate.

زيادة لايكات فيسبوك تساعد في تحسين تفاعل المنشورات وزيادة انتشارها بين المستخدمين. كلما ارتفع عدد الإعجابات، زادت فرص وصول المحتوى إلى جمهور أكبر. كما تعزز هذه الزيادة مصداقية الصفحة وتدعم العلامات التجارية وصناع المحتوى في بناء حضور أقوى وتحقيق نمو أسرع على منصة فيسبوك بشكل ملحوظ. زيادة لايكات فيسبوك

Pretty good post. I just stumbled upon your blog and wanted to say that I have really enjoyed reading your blog posts. Any way I'll be subscribing to your feed and I hope you post again soon. Big thanks for the useful info. Woodlands trash bin cleaning

Iowa lawmakers have sent the governor legislation that would double the number of medical cannabis dispensaries that are allowed to operate in the state. Under current law, Iowa’s limited medical marijuana program allows only five dispensaries. That would double to 10 under HF 990, which was approved by the House of Representatives in an 88-5 vote last month and previously cleared the Senate in a tally of 42-5. The bill is now before Gov. Kim Reynolds (R), who can sign or veto it, or allow it to become law without her signature. Bridget Spiddle, public policy and communications coordinator for the Marijuana Policy Project (MPP), wrote in an action alert to supporters that the reform “would be a vital step in expanding medical cannabis access for one of the most restrictive medical cannabis programs in the country.” “No other medication gets treated like cannabis does. Pharmacies are widely accessible throughout Iowa, while dispensaries are capped at five locations for thousands of patients,” she said. “Rural Iowans have to expend enormous amounts of time and resources on costly travel to receive their medicine.” In addition to doubling the dispensary allowance, the proposal before the governor would also allow out-of-state residents to register in the medical cannabis program if they have a certification from an Iowa healthcare provider. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — The Iowa Medical Cannabidiol Board, which oversees the state’s medical marijuana program, recommended in a 2023 report that the state allow more licenses “in an effort to provide Iowans with greater geographical access to medical cannabis products.” Under the program, patients with certain conditions can obtain cannabis products containing no more than at 4.5 grams of THC every 90 days. Flower and smoking are not allowed. Healthcare practitioners can allow greater amounts of THC for patients who are terminally ill or who have experience with the program and for whom the provider believes 4.5 grams is not enough. Separately this session, Iowa lawmakers are considering a bill to create a state-regulated therapeutic psilocybin program for patients with post-traumatic stress disorder (PTSD). Last year, the governor vetoed separate legislation that would have allowed doctors in the state to immediately prescribe a synthetic form of psilocybin in the event of federal approval of the psychedelic substance by the U.S. Food and Drug Administration (FDA), arguing that it “surrenders state authority to make an informed determination about classification to federal officials.” Photo courtesy of Kimzy Nanney. The post Iowa Bill To Double The Number Of Medical Marijuana Dispensaries Heads To Governor’s Desk appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I am glad you take pride in what you write. This makes you stand way out from many other writers that push poorly written content. 성인 피시방

This particular is usually apparently essential and moreover outstanding truth along with for sure fair-minded and moreover admittedly useful My business is looking to find in advance designed for this specific useful stuffs… fujiwin88

ATF changes marijuana question on gun form; MA lawmakers pass on anti-cannabis measure; CT psychedelics bill to gov; IN GOP legalization bill Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Free to read (but not free to produce)! We’re proud of our newsletter and the reporting we publish at Marijuana Moment, and we’re happy to provide it for free. But it takes a lot of work and resources to make this happen. If you value Marijuana Moment, invest in our success on Patreon so we can expand our coverage and more readers can benefit: https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW The Drug Enforcement Administration announced it will soon launch registration forms for state-licensed medical marijuana manufacturing, distribution and testing businesses that want to take advantage of federal protections under rescheduling—building on an existing form for dispensaries. The agency also recently updated its lists of controlled substances to formally note that marijuana subject to a state medical cannabis license falls under Schedule III. The Bureau of Alcohol, Tobacco, Firearms and Explosives posted draft revisions to a gun purchase form that would recognize medical marijuana’s federally legal status following the Trump administration’s rescheduling move. The Massachusetts legislature’s Special Joint Committee on Initiative Petitions recommended that lawmakers not act on a proposal to roll back the state’s marijuana legalization law, leaving prohibitionist activists to collect additional signatures to place it on the November ballot. Connecticut lawmakers sent Gov. Ned Lamont (D) a bill to expand a psychedelic pilot program to let all adults who meet eligibility criteria participate—instead of just veterans, retired first responders and healthcare workers—in anticipation of federal approval of psilocybin or MDMA. An Indiana Republican senator announced plans to file a bill to legalize medical cannabis in the 2027 session in light of Gov. Mike Braun’s (R) recent comments on the issue and as reform advances at the federal level under the Trump administration. Historian Emily Dufton highlights in a new Marijuana Moment op-ed how the Trump administration’s cannabis rescheduling move is focused on helping ailing seniors, but says she’s “concerned that this project was rolled out quickly with vocal support but little coordination.” “The rush to provide senior citizens with medical marijuana will require considerable legal, scientific and commercial infrastructures, which, in an ideal world, would avoid repeating historical mistakes by forming with clarity and coordination.” / FEDERAL President Donald Trump said his administration is “looking very seriously” at approving “natural 7-OH.” The Drug Enforcement Administration promoted an article about how “cannabis triggered one teen’s downfall from excelling at sports and having a bright future at college to suffering from a ‘God complex.'” / STATES Colorado regulators filed proposed changes to marijuana rules. Vermont regulators published guidance on cannabis cultivation tier increases. Ohio officials are launching a public education campaign about “the health and safety risks of marijuana use.” New York cannabis regulators are extending the application deadline for the Community Grants Reinvestment Fund to May 21. New Jersey regulators sent a newsletter with updates on various cannabis issues. The Nevada Cannabis Advisory Commission’s Subcommittee on Taxation will meet on Thursday. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / LOCAL San Francisco, California is seeing a surge in arrests and citations for low-level drug crimes, but not for sales, under a crackdown championed by the mayor. / INTERNATIONAL The International Criminal Court unsealed an arrest warrant for a Philippine senator linked to that county’s bloody “war on drugs.” Pakistan’s Economic Coordination Committee approved additional funds for the Cannabis Control and Regulatory Authority. / SCIENCE & HEALTH A study found that “legalization reduces cannabis possession and sales arrests for White and Black populations, narrowing but not eliminating disparities,” that there are “spillover increases in hospitalizations involving cannabis and other illegal drugs,” that “spillovers on arrests, incarcerations, and crimes involving serious violent or property offenses are insignificant or even decrease” and that “other illegal drug sales arrests decrease across populations.” / BUSINESS Cannara Biotech Inc. completed its acquisition of Medican Organic Inc. Cronos Group Inc. reported quarterly net revenue of $45.2 million and a comprehensive loss of $3.3 million. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: Photo courtesy of Chris Wallis // Side Pocket Images. The post DEA launching new cannabis business registration applications (Newsletter: May 12, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Outstanding article! I want people to know just how good this information is in your article. Your views are much like my own concerning this subject. I will visit daily your blog because I know. It may be very beneficial for me. login nagawin

Leave normality behind and indulge your desires in a night filled with passion and sensuality with an amazing partner who appreciates every moment you spend with one another, by using the trusted Delhi escort service for a romantic rendezvous. Dhaula Kuan Escorts Service | Dilshad Garden Escort | Escort in East of Kailash | Golf Course Road Escorts | Escorts in Prithviraj Road |

Our agency delivers exclusive companionship services with a commitment to comfort, trust, and customer satisfaction. We carefully manage every interaction to ensure clients feel relaxed and valued throughout the experience. Choosing an Escort in Ashok Vihar through us means receiving dependable and professionally managed companionship assistance.

The sensual moves you will experience with the Female Call Girl Lucknow are incredibly exciting and alluring. You might be unaware of these girls' acts and maneuvers if you've never been to a tantalizing encounter with an independent woman.

“The rush to provide senior citizens with medical marijuana will require considerable legal, scientific and commercial infrastructures, which, in an ideal world, would avoid repeating historical mistakes by forming with clarity and coordination.” By Emily Dufton Everyone knows that last month was historic for cannabis. Big changes are afoot with medical marijuana’s rescheduling and federal Medicare coverage for hemp. But what many have misunderstood is why. For the first time in 56 years, a form of marijuana has finally escaped Schedule I of the Controlled Substances Act (CSA). Cannabis was placed there in 1970, and despite repeated prior legalization attempts—including in the 40 states that legalized medical access and the 24 states that legalized recreational use—for over half a century cannabis remained stubbornly defined as a substance with no accepted medical use and high potential for abuse. Until last month, when Acting Attorney General Todd Blanche moved medical marijuana into Schedule III, a category of drugs with some accepted medical use and “moderate-to-low” potential for dependence. This rescheduling includes medical products currently legal in 40 states and Washington, D.C., and the four cannabis products approved by the Food and Drug Administration (FDA). These products are now all Schedule III, which means dispensary owners aren’t subject to heavy tax burdens like 280E. Medical marijuana just became a much more legitimate industry. But what makes this shift even more historic is who it’s intended to benefit: senior citizens. Previous legalization movements all centered on young adults. The decriminalization movement of the 1970s painted cannabis as a maturing baby boomer’s “adult right.” Activists in the 1980s and ’90s argued that medical marijuana was necessary for young men struggling with HIV/AIDS. And in the 2010s and 2020s, the social justice movement promoted legalization as a means to end the mass incarceration of young Black men. Recriminalization movements have been equally concerned with the effect of pot on kids. The zero-tolerance, “Just Say No” drug war of the Reagan 1980s was launched explicitly to save the children. And intoxicating hemp products, accidentally legalized in the 2018 Farm Bill, are scheduled to be made illegal again this November, after opponents warned that they have sent too many children to the emergency room. But the Trump administration’s vocal support for rescheduling medical marijuana is based on something new: concern for the 18 percent of Americans—almost 1 in 6—who are over the age of 65, a number expected to rise to almost a quarter of the population by 2050. A new industry is rising to serve this demographic. Howard Kessler, of the Commonwealth Project, is one of the most vocal proponents of seniors’ medical marijuana use. A video from the Project (which Trump reposted on Truth Social last September) seemed to address the president directly. “You can revolutionize senior health care,” the narrator begins, before listing cannabis’s positive effects on pain, stress, and sleep. The video closes by promising that, “You will deliver the most important senior health initiative of the century, cementing your legacy and transforming aging care. Millions everywhere will thank you.” As a drug historian, I did not see this coming. Medical marijuana’s historic rescheduling is being praised as a win for senior citizens, a demographic that almost never entered the conversation before. For years, prohibitionists argued that today’s cannabis products are too strong, a far cry from yesterday’s tamer, weaker weed. But with these new senior-directed products, this actually is your grandma’s marijuana. The baby boomers who fought for decriminalization in the 1970s are getting it, in 2026, with federal funding from Centers for Medicare & Medicaid Services Director Dr. Mehmet Oz. By centering senior health and wellness, Kessler’s campaign successfully upended decades of drug policy concerns over kids, and this shift will have major impacts on both legalization and re-criminalization campaigns. The attitude of “save the children” that changed laws before might not work when marijuana’s intended users are senior citizens. But a backlash could form just as quickly if unregulated “medical” products start hurting Grandma. That’s why, as a historian, I’m also concerned that this project was rolled out quickly with vocal support but little coordination. There’s a distinct lack of clarity about how this transformation will work. Given marijuana’s half-century in Schedule I, the science behind cannabis medicine is still inchoate. It’s also not entirely clear who’s in charge, since numerous entities are involved with the shift, including the Drug Enforcement Administration, FDA, Department of Justice and Internal Revenue Service, as well as legislative, regulatory and law enforcement bodies at the state and local level. And so far no one has addressed its impact on the hemp/marijuana divide. A lack of coordination doomed previous legalization campaigns, and it may harm rescheduling if rolled out in a chaotic manner. At the moment, the outlook doesn’t look promising. As Dr. Gillian Schauer, executive director of the Cannabis Regulators Association, told NPR, “We have been implementing policy that’s far ahead of where the science is… It’s like we’re flying the plane blind while building it without parts.” Last month’s rescheduling was historic, but it’s also incomplete. The rush to provide senior citizens with medical marijuana will require considerable legal, scientific and commercial infrastructures, which, in an ideal world, would avoid repeating historical mistakes by forming with clarity and coordination. It may not be happening yet, but it’s what Grandma deserves. Emily Dufton is the author of Grass Roots: The Rise and Fall and Rise of Marijuana in America and Addiction, Inc.: Medication-Assisted Treatment and America’s Forgotten War on Drugs. The post Trump’s Medical Marijuana Move Focused On Helping Ailing Seniors, But Lack Of Coordination Could Cause Backlash (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

An Indiana Republican state senator has announced plans to file legislation to legalize medical marijuana in the 2027 session in light of recent comments from the governor about the issue and as reform advances at the federal level under the Trump administration. “In light of the governor’s openness to consider legislation regarding the legalization of marijuana, we need to consider a feasible marijuana policy that would be the most helpful to Hoosiers and the economy,” Sen. Mike Bohacek (R) said in a press release on Monday. “The use of medical marijuana has been proven to be beneficial for some medical disorders and could help people throughout the state who are suffering find some relief.” Gov. Mike Braun (R) recently said the state is “more likely” to legalize marijuana now that the Trump administration is moving to federally reschedule cannabis. Bohacek said his bill will include “plenty of parameters around the implementation and use of medical marijuana to ensure it’s being properly regulated and distributed by Hoosier healthcare professionals.” “There are plenty of benefits medical marijuana can have, not only in a healthcare capacity, but also on our economy. Indiana has already allowed the sale of delta-8 THC and other similar cannabinoids, so creating a tax policy is a logical next step in expanding the use of THC products. There is potential to bring in millions of dollars in tax revenue every year.” The senator’s press release says the planned legislation will update current laws by establishing a blood concentration that would define THC impairment and create trainings to help law enforcement identify people who are under the influence. “While the legislation I plan to propose would legalize the use of medical marijuana, it would not take away from the safety standards that would need to be established to keep Hoosiers safe,” Bohacek said. “This proposed legislation would not legalize the use of recreational marijuana. Many of our state’s current laws regarding the use of marijuana would remain in place, with some adjustments to account for those who may have medical exemptions,” he said. “This is why I am also working on legislation that would adjust the state impairment laws for those who would use medical marijuana.” The senator is encouraging constituents to contact him with “any questions or comments they may have” about the forthcoming cannabis legislation. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Last month, U.S. Sen. Jim Banks (R-IN) sent a letter urging the governor to “maintain the state’s prohibitions on marijuana use” despite federal reform. Under an order signed last month by U.S. Acting Attorney General Blanche, marijuana products regulated by a state medical cannabis license immediately moved from Schedule I to Schedule III of the federal Controlled Substances Act (CSA), as did any marijuana products that are approved by the Food and Drug Administration (FDA). “I think the fact that the feds made that move, that makes it more likely” the state will act to reform its cannabis laws, the governor said recently. “You’re going to need to ask the legislators and the leaders in those two chambers to see what they’re thinking, because I’m clear in terms of where I’m at,” Braun continued. “You’ve got to take what’s evolved over time. [If you] stick your head in the sand, you’re generally going to make the wrong decision.” Meanwhile, at Braun’s direction, state officials have been holding a series of meetings with medical marijuana advocates. In March, the governor said the “crescendo will rise” in the call to legalize marijuana, with regional dynamics and even law enforcement buy-in favoring reform down the line. But for now, he said GOP legislative leadership in the state is “not interested in doing anything soon,” even if “over half of Hoosiers probably smoke it illegally.” Braun said at the time that he thinks lawmakers should take “an additional look at” medical cannabis and that, while he’s personally “agnostic” on legalization, the reality is that Indiana is “surrounded now by four states” that allow either medical or adult-use cannabis. “Over half of Hoosiers probably smoke it illegally,” he said, noting that neighboring Kentucky permits patients to access medical cannabis, while Illinois, Michigan and Ohio have recreational marijuana laws on the books. “I’m going to listen to law enforcement. Even they have changed their opinion in terms of legalizing it and regulating it,” Braun said, adding that he’d compare cannabis to gambling. The state was late in the game to adopt laws allowing adults to gamble, he said, but now it ranks in the top three states nationwide in terms of revenue per capita from the vice. “Some people aren’t going to want it, just out of principle. A lot of our state police and sheriffs are tolerating people going across the border [to buy cannabis]. It’ll be an increasing issue that, so far, our state legislature has kind of dug in against it,” he said. “I’ve been more agnostic about it. I can see points of view, and I’ve seen law enforcement move on it somewhat.” “So that would give you the best description of where the dynamic is in our state,” the governor told WOWO. “I think the leader of the Senate especially, and the Speaker of the House, are pretty—and they control the legislative agenda—not interested in doing anything soon. But I think the crescendo will rise, and that describes in a snapshot where we’re at.” Braun similarly talked about the issue in another recent interview, saying the state is “probably going to have to address” the issue and likening cannabis reform to sports betting. Lawmakers in the state had already signaled that marijuana legalization isn’t in the cards in the 2026 session, meaning another year where Indiana will be an outlier as one of the few remaining states without effective medical or adult-use cannabis laws. The governor separately said in January that he’s “amenable” to the idea of legalizing medical cannabis in the state. Instead, Indiana legislators this session have been focused on efforts to ban hemp THC products—though it seems that fight is over for 2026 after a last-minute push failed in February. Braun has previously said that federal marijuana rescheduling could add “a little bit of fire” to the local push for cannabis legalization in his state. Among Indiana residents, a survey released in January found that nearly three in five back legalizing cannabis for medical and recreational use. Specifically, the annual Hoosier Survey from the Bowen Center at Ball State University (BSU) found that 59 percent of residents are in favor of legalizing cannabis for both medical and recreational purposes. An additional 25 percent back only allowing patients to access medical marijuana, raising the total support for that reform to 84 percent. Braun, for his part, previously said that “it’s probably time” to allow access to therapeutic cannabis among patients in the state. Those comments came alongside a separate poll indicating that nearly 9 in 10 Indiana adults (87 percent) support marijuana legalization. Top Republicans in the legislature, however, have openly opposed marijuana reform. “It’s no secret that I am not for this,” Senate President Pro Tem Rodric Bray (R) said in late 2024. “I don’t have people coming to me with really compelling medical cases as to why it’s so beneficial. And any state that I’ve seen pass medical marijuana is essentially passing recreational marijuana.” House Speaker Todd Huston (R) doubted any medical benefits associated with marijuana, calling the substance “a deterrent to mental health.” He and others suggested that lawmakers supportive of the reform merely want to boost state revenue. The post Indiana GOP Senator Announces New Bill To Legalize Medical Marijuana In The State appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The federal Drug Enforcement Administration (DEA) has announced it will soon be rolling out new forms for additional types of state-licensed medical marijuana businesses beyond dispensaries that want to take advantage of federal protections in line with the Trump administration’s cannabis rescheduling process. Last month, DEA launched a registration form for medical marijuana dispensaries only, raising questions about how operators elsewhere along the cannabis supply chain could become federally compliant during a 60-day registration window for expedited processing that is scheduled to close on June 26. But now, the agency says that “in the coming weeks, an updated ‘Medical Marijuana Manufacturer’, ‘Medical Marijuana Bulk Manufacturer (grower/cultivator)’, ‘Medical Marijuana Analytical Lab’, and ‘Medical Marijuana Distributor’ application will be available specifically for handling Schedule III medical marijuana and posted on DEA Diversion’s Registration page.” It’s not clear exactly how soon those forms will be posted, however. In any case, the various DEA cannabis business registration portals are being launched following last month’s announcement by the Department of Justice that marijuana is being moved from Schedule I to Schedule III of the Controlled Substances Act (CSA), in phases. Under an order signed by Acting Attorney General Blanche, marijuana products regulated by a state medical cannabis license immediately moved to Schedule III, as did any marijuana products that are approved by the Food and Drug Administration (FDA). The currently available registration form for state-licensed medical marijuana dispensaries asks for information about their processes for storage, ordering, dispensing, inventory, maintenance of records and other aspects of their businesses. The application asks about specific details about security measures such as vaults, safes, secure storage rooms, access controls, alarm systems and on-site security personnel. Applicants can choose whether they are requesting to handle marijuana, marijuana extracts or naturally derived delta-9 THC. While only medical marijuana is currently being moved to Schedule III, the application also asks potential registrants whether their firms handle or dispense recreational marijuana. Under last month’s DOJ order there will be an expedited administrative hearing process to consider the broader rescheduling of cannabis from Schedule I to Schedule III, beginning on June 29. The DEA application, meanwhile, also asks businesses to submit information about their state cannabis licenses and to answer questions about criminal and disciplinary histories. It also asks: “Has anyone who will be involved in the ownership or operation of the firm previously manufactured, distributed, and/or dispensed any controlled substance without a DEA registration authorizing such activity?” Presumably, every currently operational state-legal cannabis business has key personnel who have done so, since medical marijuana was, until just days ago, a Schedule I controlled substance that DEA did not broadly authorize manufacturing, distribution and dispensation of. Applicants must additionally list suppliers from which they intend to procure marijuana, and to disclose whether they anticipate repackaging or relabeling cannabis products. They also need to provide lists of individuals with the business that are anticipated to have “access to controlled substances,” including their dates of birth, social security numbers, criminal histories related to drugs. There is also an annual $794 application fee, currently only payable via PayPal, though DEA says “we anticipate having additional forms of payment in the coming weeks.” Application fees are not refundable. In addition to the notice about the forthcoming DEA registration forms for other types of cannabis businesses, the agency also recently updated its lists of controlled substances to formally note that marijuana subject to a state medical cannabis license falls under Schedule III. Blanche’s rescheduling order said that to align with an international drug control treaty “requirement that a government agency serve as the exclusive purchaser of cannabis production,” DOJ is rolling out a process by which the federal government will technically purchase marijuana from producers and then sell it back to them or related entities. “Registered manufacturers must store crops in a facility to which DEA maintains access until that transaction is complete, and each manufacturer registration must specify the areas in which cultivation is permitted,” it said. “All manufacturers registered under this subsection shall establish a nominal price for the purchase of their marijuana crops. The Administration shall then purchase the entity’s crops at that price and sell the crops back to the entity, or a related or subsidiary entity, at the same price with the addition of the administrative fee as calculated under Part 1318.06(a).” Meanwhile, the U.S. Department of the Treasury and Internal Revenue Service (IRS) said they plan to issue new tax guidance for the marijuana industry following the rescheduling announcement. Rescheduling will benefit state-licensed marijuana businesses by allowing them to take federal tax deductions they’re currently barred from under an IRS code known as 280E that doesn’t apply to Schedule III substances. The Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) also recently posted a draft update to gun purchase form to acknowledge the federally legal status of medical marijuana under rescheduling. The Congressional Research Service published a report on the marijuana rescheduling move’s scope and limitations. White House Press Secretary Karoline Leavitt said that the administration is moving forward with marijuana rescheduling because cannabis reform is “overwhelmingly popular” with voters and because doing so will help people who need access to the drug for medical purposes. During a press event in the Oval Office, President Donald Trump spoke about the medical benefits of marijuana. “A lot of people are suffering from big problems, which this seems to be the best answer,” he said. “They’re very happy about it. So the rescheduling is starting, and that’s a big thing, rescheduling.” The president noted that his administration’s actions on cannabis rescheduling came after his friend Howard Kessler told him about how he used medical marijuana. “He had some medical difficulties, and he came upon this by accident, in a way,” he said. “He had to go through a lot of different medications, and he said this was the one that was much better than anything else. And so he experienced that. He didn’t benefit by it, other than from the standpoint that he lives a much better life now.” “So hopefully you don’t need it,” Trump said. “But if you do need it, I hear it’s the best of all the alternatives.” Separately, the president called on Congress to take action to amend a law that threatens to federally recriminalize hemp-derived full-spectrum CBD products later this year. “We must get this done RIGHT and FAST, especially for those who saw that CBD helps them,” he said in a social media post. “Plus, I am told it will also help our GREAT FARMERS, who we love, and will always be there for.” Days earlier, Trump had complained that federal officials were “slow-walking” following through on his cannabis order. The post DEA Announces New Marijuana Registration Forms For Manufacturing, Distribution And Testing Businesses appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Connecticut lawmakers have sent the governor a bill to expand a pilot program that’s meant to explore the therapeutic potential of psychedelics such as psilocybin and MDMA. The legislation sponsored by the Joint Committee on Public Health cleared the House of Representatives in 122-27 vote on Wednesday after being approved unanimously by the Senate last month. It now heads to the desk of Gov. Ned Lamont (D). If enacted into law, the proposal would build upon an existing psychedelic-assisted therapy program involving military veterans and first responders who elect to participate in clinical trials. The new legislation would repeal and replace the current statute to make it so any adults 18 or older who meet clinical eligibility criteria established by the institutional review board of the medical school selected to administer the pilot program could be eligible to receive psychedelics treatment in a clinical setting, with researchers tasked with studying the efficacy of the novel therapeutics. It would also remove existing language stipulating that the pilot program must end upon federal approval of psilocybin or MDMA by the Drug Enforcement Administration (DEA) or a successor agency. Additionally, the bill would strike outdated language requiring the state Department of Mental Health and Addiction Services to create and facilitate the program by January 2023. Rep. Cristin McCarthy Vahey (D) said the legislation is “critically important,” citing recent moves by federal officials to expedite research on and therapeutic access to psychedelics after President Donald Trump signed an executive order on the issue last month. “If the fast track is successful and these drugs are approved, our study will end, making us effectively unable both to continue the study and losing the benefit of the investment we’ve already made as a state—but in addition making us ineligible for those federal matching funds,” she said on the floor ahead of the most recent vote. Under the Connecticut bill, SB 191, the officials would be mandated to “establish, within available appropriations, a psychedelic-assisted therapy pilot program, to be administered by a medical school in the state.” That program “shall provide qualified patients with MDMA-assisted or psilocybin-assisted therapy as part of a research program approved by the federal Food and Drug Administration,” or FDA, it says. Rep. Nicole Klarides-Ditria (R) also spoke in support of the legislation, saying “this expanded access is for innovative research. It’s evidence-based research. Mental health and the treatment is critical for the state of Connecticut.” “Expanding it to anybody 18 and older is truly going to help us continue with this pilot program,” she said. To that point, McCarthy Vahey said that under the current structure’s restrictions there has been difficulty recruiting enough participants. “The current pilot is narrowly focused and tailored. And in fact, it will remain the priority to have veterans, first responders and our direct health care workers be the focus of the study,” she said. “But we are being told that some of the folks are having a little difficulty with recruiting. The goal is to get to a cohort of 50, and so this will give them a little bit of leeway to do so.” Rep. Dave Yaccarino (R) noted that he voted against the original psychedelics program legislation a few years ago but said he has since learned about studies showing benefits for “men and women that come in from combat, our firefighters, our police that see tragic events.” “If this helps, and it’s controlled, I think you have to support it,” he said. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, last year, the Connecticut House of Representatives approved a bill to decriminalize psilocybin for adults—despite questions about whether the governor would support it after he rejected an earlier version of the reform measure. That marked the third session in a row that Connecticut lawmakers worked to advance psilocybin decriminalization. In 2023, the reform measure cleared the House but did not move through the Senate. The Judiciary Committee also approved a version in 2024. Lamont also signed a large-scale budget bill in 2022 that included provisions to set the state up to provide certain patients with access to psychedelic-assisted treatment using substances like MDMA and psilocybin. Lawmakers also sent the governor legislation this session to address cannabis product THC potency limits. Separately, legislation to allow medical marijuana use by certain qualifying patients at health facilities such as hospitals, nursing homes and hospices received a committee hearing but did not advance. The post Connecticut Bill To Expand Psychedelics Pilot Program In Anticipation Of FDA Approval Heads To Governor’s Desk appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Massachusetts lawmakers have decided not to take up a proposal that would scale back the state’s voter-approved marijuana legalization law, leaving it to prohibitionist activists to collect additional signatures to place the initiative on the November ballot. The legislature’s Special Joint Committee on Initiative Petitions issued a report last week saying that a majority of the panel “voted to recommend that the General Court take no action” on the measure. Under state law, the legislature gets a chance to enact proposed ballot measures after organizers submit an initial round of petitions. If they decline, campaigns can then collect more signatures to refer initiatives to voters. After conducting a review, a majority of committee members “raised substantial concerns regarding the structure, scope, and anticipated impacts” of the proposal, which would repeal state laws allowing the regulated commercial sales of recreational marijuana while continuing to keep the medical cannabis system in place. “The Committee notes that this existing framework represents a comprehensive regulatory system that has been developed over time to balance public health protections, consumer access, and a legal, taxed marketplace for cannabis products,” the panel’s report says. “The Committee finds that the proposal lacks sufficient detail regarding implementation and enforcement mechanisms, including how existing regulatory authority would be modified, transferred, or eliminated. This absence of clarity creates legal uncertainty with respect to the continued applicability of current statutes and regulations, as well as the roles of state agencies responsible for oversight of the cannabis industry.” The report also says that members are concerned the anti-cannabis ballot measure would undermine “public health and safety safeguards,” including “measures designed to limit youth access to cannabis products, reduce impaired driving risks, and ensure product testing, labeling, and potency standards.” “Testimony presented to the Committee highlighted concerns that weakening or eliminating these safeguards could increase public health risks and undermine efforts to promote responsible use within a legal market,” it says. The panel additionally flagged the proposal’s implications for licensing and taxation, saying that “abrupt changes to the current system could disrupt licensed businesses operating in compliance with existing law, create uncertainty in the investment environment, and affect the stability of both large and small operators in the industry.” “Testimony also raised concerns with the proposal regarding substantial impacts on state and local revenue streams derived from cannabis taxation and licensing fees, which currently support a range of public programs and local initiatives, as well as the regulatory structure,” members wrote. “The majority of the Committee therefore finds that, as drafted, the proposal does not adequately address these operational, fiscal, and public safety considerations,” the panel’s report says. Proponents faced skeptical questioning from lawmakers at a hearing of the committee last month, with several members raising concerns about the motivations behind the anti-marijuana measure and its implications for consumers and businesses. Organizers behind the measure must now collect an additional 12,429 certified signatures by July 1 to make the November ballot. Meanwhile, the measure is facing a legal challenge from cannabis industry operatives who say it contains “impermissibly unrelated subjects,” and that the state attorney general’s official summary is “misleading and deficient.” The initiative also proposes “an unconstitutional regulatory taking” by “destroy[ing] the reasonable, investment-backed expectations of affected businesses and individuals and would eliminate the livelihoods of thousands of Massachusetts residents,” the lawsuit, brought by participants in the state’s Cannabis Social Equity Program, says. The state Supreme Judicial Court heard oral arguments on the litigation challenging the anti-marijuana initiative last week. If the “Act to Restore Sensible Marijuana Policy” is passed, the state wouldn’t revert back to blanket prohibition; rather, it would repeal the commercial recreational sales and personal home cultivation components of the law while still allowing adults 21 and older to possess up to an ounce of cannabis for personal use. Possession of more than one ounce but less than two ounces would be effectively decriminalized, with violators subject to a $100 fine. Adults could also continue to gift cannabis between each other without remuneration. Medical marijuana sales would remain legal. A recent Bay State Poll from the University of Hampshire’s States of Opinion Project found that a majority of Massachusetts adults oppose the marijuana sales and cultivation repeal initiative. The survey came months after cannabis activists filed a complaint with the State Ballot Law Commission, alleging that petitioners with the anti-cannabis campaign used misleading tactics to convince voters to support its ballot placement. The commission rejected the complaint in January, however, and said advocates who challenged the ballot measure raised “unsupported allegations” about the propriety of the signature gathering process that they said warranted official scrutiny. In any case, separate polling has found that nearly half of those who signed the marijuana sales repeal petition felt misled, with many claiming that the measure was pitched to them as a proposal to address unrelated issues such as public education and expanded housing. The anti-marijuana coalition has denied any wrongdoing in the signature collection process and waved off the survey results. An association of state marijuana businesses had separately urged voters to report to local officials if they observe any instances of “fraudulent message” or other deceitful petitioning tactics. Meanwhile, the head of Massachusetts’s marijuana regulatory agency recently suggested that the measure to effectively recriminalize recreational cannabis sales could imperil tax revenue that’s being used to support substance misuse treatment efforts and other public programs. To that point, Massachusetts recently reached another marijuana milestone, with officials announcing in February that the state has surpassed $9 billion in adult-use cannabis purchases since the market launched in 2018. A report from the Cannabis Control Commission (CCC) found that legalization is achieving one of its primary goals: disrupting illicit cannabis sales as adults transition to the regulated market. It shows that among adults who reported past-year marijuana use, an overwhelming 84 percent said they obtained their cannabis from a licensed source. The state’s governor recently signed into law a bill to double the legal marijuana possession limit for adults and revise the regulatory framework for the state’s cannabis market. In December, state regulators also finalized rules for marijuana social consumption lounges. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — CCC recently launched an online platform aimed at helping people find jobs, workplace training and networking opportunities in the state’s legal cannabis industry. Massachusetts lawmakers additionally approved legislation to establish pilot programs for the regulated therapeutic use of psychedelics. Photo courtesy of Mike Latimer. The post Massachusetts Lawmakers Decline To Act On Measure To Roll Back Marijuana Legalization appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A federal agency is proposing to update a gun purchase form to acknowledge the federally legal status of medical marijuana under the Trump administration’s recent move to reschedule the drug. The Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) on Friday posted a proposed revised version of Form 4473, which must be filled out by anyone purchasing a gun from a federally licensed firearms dealer. For years, the document has contained a question that asks whether the buyer unlawfully uses cannabis or other federally controlled substances, in accordance with a law that makes it a crime for such persons to possess or purchase firearms. Until now, the question has read: “Are you an unlawful user of, or addicted to, marijuana or any depressant, stimulant, narcotic drug, or any other controlled substance? Warning: The use or possession of marijuana remains unlawful under Federal law regardless of whether it has been legalized or decriminalized for medicinal or recreational purposes in the state where you reside.” But under ATF’s new form, which is part of a suite of new administrative steps intended to reduce burdens on firearms owners and businesses, guy buyers would instead have to attest to the following statement: “I am not an unlawful user of, or addicted to, marijuana or any depressant, stimulant, narcotic drug, or any other controlled substance. (Warning: You can be an unlawful user under federal law, even if your possession is legal under state law. Federal law does not permit the use or possession of marijuana for recreational purposes.)” The section notably says that only “use or possession of marijuana for recreational purposes” is federally prohibited, leaving out the prior form’s mention of medical cannabis. The change is likely due to the fact that last month, Acting Attorney General Todd Blanche issued an order that immediately moved marijuana products regulated by a state medical cannabis license to Schedule III of the Controlled Substances Act (CSA), and similarly rescheduled marijuana products that are approved by the Food and Drug Administration (FDA). A hearing to consider broader cannabis rescheduling is scheduled for this summer. The Congressional Research Service published a report on the current cannabis rescheduling move explaining that certified patients who possess medical marijuana from state-licensed dispensaries now have certain protections under Schedule III. “The order appears to authorize end users to possess marijuana for medical use without a CSA-compliant prescription,” it says. ATF is accepting public comments on the revised gun purchase form through July 7. Kostas Moros, director of legal research and aducation for the Second Amendment Foundation (SAF), told Marijuana Moment that the group is “happy to see that the ATF’s new draft form 4473 already takes into account its recently announced rescheduling of cannabis, and thus the form no longer includes medical marijuana use or possession as disqualifying.” Separately last month, Blanche suggested that the Trump administration may soon stop aggressively defending 922(g)(3), the federal law that criminalizes gun possession by people who consume marijuana and other illegal drugs. A reporter asked the acting attorney general at a briefing on the administration’s new gun policies whether DOJ is “reconsidering” its stance of defending laws disarming marijuana consumers or those who have other nonviolent convictions from legal challenges under the Second Amendment. “Yes, of course we are,” he said. “Every case is different. The facts leading up to where we are in a litigation is different, whether we’re at the district court level, whether we’re at the court of appeals.” “It’s not rational, or it’s not possible for us to just unwind on a given Monday. We just recently got out of a case two weeks ago that had been pending for a long time,” Blanche said. “We’ve recently argued some cases in front of the Supreme Court. We’ve had some cases in the court of appeals, and this is something that we’re looking carefully at case by case to make sure that we are doing the right thing—consistent with the Constitution, consistent with the Second Amendment, consistent with this administration’s priorities.” “And so yes, it’s not as smooth as a single day, but it’s also not as clunky as taking forever,” the attorney general said. In March, however, the Trump administration argued before the U.S. Supreme Court that the federal law barring cannabis consumers from owning guns is constitutional under the Second Amendment. And last month, Solicitor General D. John Sauer sent the justices a letter saying that the Trump administration’s move to federally reschedule marijuana should not impact their decision in that case, U.S. vs. Hemani. Moros of SAF told Marijuana moment that ATF “may soon be forced to revise the form even further following what we hope will be a favorable ruling” in that case. Separately, ATF moved earlier this year to loosen rules that bar people who consume marijuana and other illegal drugs from being able to lawfully purchase and possess guns by making it so fewer people would be affected. The interim final rule from ATF, which is currently open for public comment through June 30, seeks to update the definition of “unlawful user of or addicted to any controlled substance” under an existing policy that has been interpreted to deny Second Amendment rights to people who have used illegal substances a single time within the past year. The post New ATF Gun Form Recognizes Medical Marijuana’s Federally Legal Status Under Trump’s Rescheduling Move appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Its a great pleasure reading your post.Its full of information I am looking for and I love to post a comment that "The content of your post is awesome" Great work. 피씨천국